Drug Trial Radar · NCT02216357
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
Last checked: Nov 19, 2026Latest source record: May 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Aug 2014
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a \> 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study Day 1 or 2) prior to initiation of the aspirin challenge.
Conditions
- Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral CapsuleDrug
Placebo, Oral CapsuleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational Medicinal Product (IMP) (Study Day 1 or 2) Prior to Initiation of the Aspirin ChallengeTime frame: Study Day 2
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Scripps Clinic
San Diego, California
Kansas City Allergy and Asthma Associates, PA.
Overland Park, Kansas
Allergy & Asthma Consultants of Rockland & Bergen
West Nyack, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.